Synthesis of thromboxane B2 - [PDF Document]

T1 - Aspirin dosage and thromboxane synthesis in patients with vascular disease

Synthesis of thromboxane B2 - ScienceDirect

5. Armstrong PC, Truss NJ, Ali FY, et al: Aspirin and the invitro linear relationship between thromboxane A2-mediated plateletaggregation and platelet production of thromboxane A2. J ThrombHaemost 2008;6:1933-1943

Synthesis of thromboxane B2 metabolites - [PDF …

4. Eikelboom JW, Hankey GJ, Thom J, et al: Incomplete inhibitionof thromboxane biosynthesis by acetylsalicylic acid: determinantsand effect on cardiovascular risk. Circulation2008;118:1705-1712

AB - Study Objective. To determine whether urinary 11-dehydrothromboxane B2 (d-TXB2) is a marker of aspirin resistance and define the relationship between aspirin dosage and concentrations of this thromboxane metabolite. Design. Randomized, crossover study. Setting. Two outpatient clinical centers. Patients. Forty-eight patients (mean age 70 yrs) with vascular disease (52% clinical coronary artery disease, 29% cerebrovascular disease, 46% atrial fibrillation). Intervention. Levels of serum thromboxane B2 and d-TXB2 were measured after patients were treated initially with aspirin 325 mg/day for 4 weeks, then again after random assignment to receive aspirin 81, 325, or 1300 mg/day for 4 weeks, and then again after resumption of 325 mg/day for 4 weeks. Measurements and Main Results. During treatment with aspirin 325 mg/day, the mean ± SD serum thromboxane B2 level was 0.9 ± 1.2 ng/ml and median (interquartile range) was 0.4 (0.2-0.9) ng/ml. Mean urinary d-TXB2 was 16 ± 7.9 ng/mmol creatinine, with a median of 15 (9.9-23) ng/mmol creatinine with aspirin 325 mg/day. After 4 weeks of aspirin 81 mg/day, levels of serum thromboxane B2 (p


Thromboxane Biosynthesis and Platelet Function in ..

N2 - Study Objective. To determine whether urinary 11-dehydrothromboxane B2 (d-TXB2) is a marker of aspirin resistance and define the relationship between aspirin dosage and concentrations of this thromboxane metabolite. Design. Randomized, crossover study. Setting. Two outpatient clinical centers. Patients. Forty-eight patients (mean age 70 yrs) with vascular disease (52% clinical coronary artery disease, 29% cerebrovascular disease, 46% atrial fibrillation). Intervention. Levels of serum thromboxane B2 and d-TXB2 were measured after patients were treated initially with aspirin 325 mg/day for 4 weeks, then again after random assignment to receive aspirin 81, 325, or 1300 mg/day for 4 weeks, and then again after resumption of 325 mg/day for 4 weeks. Measurements and Main Results. During treatment with aspirin 325 mg/day, the mean ± SD serum thromboxane B2 level was 0.9 ± 1.2 ng/ml and median (interquartile range) was 0.4 (0.2-0.9) ng/ml. Mean urinary d-TXB2 was 16 ± 7.9 ng/mmol creatinine, with a median of 15 (9.9-23) ng/mmol creatinine with aspirin 325 mg/day. After 4 weeks of aspirin 81 mg/day, levels of serum thromboxane B2 (p

sites of thromboxane synthesis…

Reference intervals apply to patients not taking agents known toinfluence platelet function (aspirin or other nonsteroidalanti-inflammatory drugs, thienopyridines, etc). Healthy individualstaking aspirin typically have 11-dehydro-thromboxane B2concentrations below 500 pg/mg creatinine using this method.

Total synthesis of (+)-thromboxane B2 from D-glucose. …

Reference intervals apply to patients not taking agents known toinfluence platelet function (aspirin or other nonsteroidalanti-inflammatory drugs, thienopyridines, etc). Healthy individualstaking aspirin typically have 11-dehydro-thromboxane B2concentrations below 500 pg/mg creatinine using this method.